BRAF and non-small cell lung carcinoma: At data cut-off, 44 NSCLC cases with available clinical data and adequate follow-up were included, of which 23 presented BRAF V600E mutation (V600E group, 52.2%) and 21 (47.8%) displayed BRAF mutations other than V600E (non-V600E).